AbolerIS Pharma
/ 1 Rue Gaston Veil
44000 Nantes
FR
AbolerIS Pharma
Foundation date
28/11/2019
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.
Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.
IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.
Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.
Upcoming events
All events-
0411 '24
BIO-Europe® 2024 - 30th Annual International Partnering Conference
Event by: EBD Group -
1012 '24
Next-Generation Synthetic Biology
Event by: VIB -
0312 '24
BioFIT 2024
Event by: Eurasanté
Latest news
More news-
reMYND announces positive Phase 2a clinical trial results for treatment of mild-to-moderate Alzheimer’s disease
Friday November 1st 2024
Read more
-
Can we protect nerve cells from dying?
Friday November 1st 2024
Read more
-
Resistance in Candida auris, how to tackle a deadly fungus
Wednesday October 30th 2024
Read more
Jobs
More jobsMore info?
Ellen Telleir
Communication Coordinator